Stockscreener 앱 받기
22.46
0.58%
-0.13
전일 마감가:
$22.59
열려 있는:
$22.9
하루 거래량:
704.64K
Relative Volume:
0.81
시가총액:
$1.49B
수익:
$9.98M
순이익/손실:
$-154.08M
주가수익비율:
-8.7054
EPS:
-2.58
순현금흐름:
$-159.66M
1주 성능:
-1.06%
1개월 성능:
-8.74%
6개월 성능:
-37.75%
1년 성능:
-40.46%
1일 변동 폭
$22.42
$23.37
1주일 범위
$22.38
$23.37
52주 변동 폭
$20.91
$53.18
Celldex Therapeutics Inc Stock (CLDX) Company Profile
명칭
Celldex Therapeutics Inc
전화
908-200-7500
주소
53 FRONTAGE ROAD, HAMPTON
CLDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
22.46 | 1.49B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-10-07 | 개시 | Citigroup | Buy |
| 2024-09-30 | 개시 | Goldman | Neutral |
| 2024-09-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 개시 | Stifel | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2023-12-20 | 개시 | TD Cowen | Outperform |
| 2023-11-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 개시 | Wells Fargo | Underweight |
| 2021-09-17 | 개시 | Jefferies | Buy |
| 2021-09-10 | 개시 | SVB Leerink | Outperform |
| 2021-07-22 | 개시 | Guggenheim | Buy |
| 2020-02-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-07 | 개시 | Aegis Capital | Buy |
| 2016-03-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2016-03-07 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-03-01 | 개시 | H.C. Wainwright | Buy |
| 2015-08-11 | 재확인 | Brean Capital | Buy |
| 2015-08-11 | 재확인 | Oppenheimer | Outperform |
| 2015-08-11 | 재확인 | ROTH Capital | Buy |
| 2015-06-02 | 재확인 | WBB Securities | Strong Buy |
| 2014-11-17 | 재확인 | ROTH Capital | Buy |
| 2014-03-04 | 재확인 | Oppenheimer | Outperform |
| 2013-07-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-08 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-02-26 | 재확인 | Oppenheimer | Outperform |
| 2013-01-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2012-10-02 | 재확인 | Oppenheimer | Outperform |
| 2012-09-14 | 재확인 | Cantor Fitzgerald | Buy |
모두보기
Celldex Therapeutics Inc 주식(CLDX)의 최신 뉴스
Celldex Therapeutics Inc (CLDX) Recovers 7.41% From Low: Are We There Yet? - Stocks Register
Celldex Therapeutics (CLDX) Projected to Post Earnings on Monday - Defense World
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - MSN
Chronic Spontaneous Urticaria Market to Register - GlobeNewswire
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Celldex Therapeutics (CLDX) Expected to Announce Earnings on Monday - MarketBeat
What is Leerink Partnrs' Forecast for CLDX Q1 Earnings? - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $60.22 Average Price Target from Analysts - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by TSP Capital Management Group LLC - MarketBeat
Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Target Price at $60.22 - Armenian Reporter
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Celldex Therapeutics (NASDAQ:CLDX) Now Covered by UBS Group - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Hits New 12-Month LowHere's Why - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from Analysts at UBS Group - Defense World
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Q1 Earnings Forecast for CLDX Issued By Leerink Partnrs - Defense World
Sovran Advisors LLC Acquires New Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
UBS Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - MSN
Celldex stock touches 52-week low at $20.99 amid market challenges - MSN
CLDXU.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH - br.ADVFN.com
Celldex Therapeutics (NASDAQ:CLDX) Sets New 1-Year LowHere's What Happened - MarketBeat
FY2025 Earnings Forecast for CLDX Issued By Leerink Partnrs - MarketBeat
Celldex Therapeutics: Will They Get It Right After A Decade Of Failures? - Seeking Alpha
CLDX’s latest rating updates from top analysts. - Knox Daily
What is Leerink Partnrs' Estimate for CLDX FY2028 Earnings? - MarketBeat
It is Poised to be a Bull Market for Celldex Therapeutics Inc (CLDX) - SETE News
Post-Trade Analysis: Celldex Therapeutics Inc (CLDX) Slides -2.11, Closing at 23.15 - The Dwinnex
Chronic Spontaneous Urticaria Market Set to Grow Substantially - openPR
Celldex Therapeutics Inc (CLDX)’s stock performance: a year in review - US Post News
Investing in Celldex Therapeutics Inc (CLDX): What You Must Know - Knox Daily
Checking in on Checkpoint Therapeutics Inc (CKPT) after recent insiders movement - Knox Daily
Stephens initates Catalyst Pharmaceuticals Inc (CPRX) stock to an Overweight - Knox Daily
Celldex Therapeutics (NASDAQ:CLDX) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by SG Americas Securities LLC - Defense World
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock outlook - Investing.com India
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential By Investing.com - Investing.com Australia
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews - Benzinga
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Cantor Fitzgerald Forecasts CLDX FY2025 Earnings - Defense World
Celldex Therapeutics Inc (CLDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Celldex Therapeutics Inc 주식 (CLDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Martin Samuel Bates | SVP AND CFO |
Jun 14 '24 |
Option Exercise |
10.16 |
20,169 |
204,990 |
45,297 |
| Martin Samuel Bates | SVP AND CFO |
Jun 14 '24 |
Sale |
35.42 |
17,172 |
608,315 |
28,125 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 14 '24 |
Option Exercise |
10.38 |
30,000 |
311,400 |
39,074 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 14 '24 |
Sale |
34.87 |
30,000 |
1,045,962 |
9,074 |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER |
Jun 11 '24 |
Option Exercise |
2.71 |
15,000 |
40,650 |
17,115 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 07 '24 |
Option Exercise |
9.70 |
15,000 |
145,474 |
24,074 |
| Crowley Elizabeth | SR. VP & CPDO |
Jun 07 '24 |
Sale |
35.06 |
15,000 |
525,873 |
9,074 |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER |
Jun 07 '24 |
Sale |
35.26 |
45,000 |
1,586,844 |
2,115 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Jun 05 '24 |
Option Exercise |
10.38 |
9,540 |
99,025 |
35,464 |
| Heath-Chiozzi Margo | SVP OF REGULATORY AFFAIRS |
Jun 03 '24 |
Option Exercise |
10.25 |
64,658 |
662,575 |
71,752 |
0.27%
3.05%
자본화:
|
볼륨(24시간):